JPWO2022018875A1 - - Google Patents

Info

Publication number
JPWO2022018875A1
JPWO2022018875A1 JP2022538564A JP2022538564A JPWO2022018875A1 JP WO2022018875 A1 JPWO2022018875 A1 JP WO2022018875A1 JP 2022538564 A JP2022538564 A JP 2022538564A JP 2022538564 A JP2022538564 A JP 2022538564A JP WO2022018875 A1 JPWO2022018875 A1 JP WO2022018875A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538564A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP2021121960A priority Critical patent/JP7168734B2/ja
Publication of JPWO2022018875A1 publication Critical patent/JPWO2022018875A1/ja
Priority to JP2022172687A priority patent/JP2023011759A/ja
Priority to JP2026044825A priority patent/JP2026102816A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Emergency Medicine (AREA)
JP2022538564A 2020-07-22 2020-07-22 Pending JPWO2022018875A1 (cg-RX-API-DMAC7.html)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021121960A JP7168734B2 (ja) 2020-07-22 2021-07-26 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2022172687A JP2023011759A (ja) 2020-07-22 2022-10-27 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2026044825A JP2026102816A (ja) 2020-07-22 2026-03-18 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/028575 WO2022018875A1 (ja) 2020-07-22 2020-07-22 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
JPWO2022018875A1 true JPWO2022018875A1 (cg-RX-API-DMAC7.html) 2022-01-27

Family

ID=79729374

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022538564A Pending JPWO2022018875A1 (cg-RX-API-DMAC7.html) 2020-07-22 2020-07-22
JP2021121960A Active JP7168734B2 (ja) 2020-07-22 2021-07-26 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2022172687A Ceased JP2023011759A (ja) 2020-07-22 2022-10-27 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2026044825A Pending JP2026102816A (ja) 2020-07-22 2026-03-18 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021121960A Active JP7168734B2 (ja) 2020-07-22 2021-07-26 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2022172687A Ceased JP2023011759A (ja) 2020-07-22 2022-10-27 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2026044825A Pending JP2026102816A (ja) 2020-07-22 2026-03-18 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Country Status (3)

Country Link
JP (4) JPWO2022018875A1 (cg-RX-API-DMAC7.html)
KR (2) KR102550455B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022018875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
AU2022312992A1 (en) * 2021-07-21 2024-02-29 Chugai Seiyaku Kabushiki Kaisha Method for producing arylamide derivative
WO2023204259A1 (ja) * 2022-04-20 2023-10-26 中外製薬株式会社 がんの治療又は予防用医薬
EP4551558A2 (en) * 2022-07-08 2025-05-14 Nested Therapeutics, Inc. Mitogen-activated protein kinase (mek) inhibitors
JP2026522033A (ja) * 2023-07-06 2026-07-03 華健未来(成都)科技股▲フン▼有限公司 芳香族アミド誘導体およびその使用
WO2025063275A1 (ja) * 2023-09-21 2025-03-27 中外製薬株式会社 アリールアミド誘導体の製造方法
AU2024417154A1 (en) * 2024-01-01 2026-08-13 Huajian Future (Chengdu) Technology Co., Ltd. Aromatic hydrazide derivative and medical use thereof
WO2026098657A1 (zh) * 2024-11-08 2026-05-15 先声再明医药股份有限公司 作为mek抑制剂的杂环化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
KR101190912B1 (ko) * 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2012020742A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 5−置換−2−フェニルアミノ−ベンズアミド類の製造方法
CN109988105A (zh) * 2014-01-27 2019-07-09 天津滨江药物研发有限公司 作为蛋白激酶抑制剂的氮杂环类化合物及其制备方法
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
KR20230122174A (ko) * 2020-07-22 2023-08-22 추가이 세이야쿠 가부시키가이샤 아릴 아마이드 유도체를 포함하는 조성물

Also Published As

Publication number Publication date
JP2026102816A (ja) 2026-06-23
JP7168734B2 (ja) 2022-11-09
WO2022018875A1 (ja) 2022-01-27
JP2022145416A (ja) 2022-10-04
KR102550455B1 (ko) 2023-06-30
KR20220012195A (ko) 2022-02-03
JP2023011759A (ja) 2023-01-24
KR20230098762A (ko) 2023-07-04
KR20230098762A9 (ko) 2024-03-25

Similar Documents

Publication Publication Date Title
JPWO2022019329A1 (cg-RX-API-DMAC7.html)
BR122025009550A2 (pt) Método de comunicação com base em dispositivo de múltiplos enlaces de transmissão e recebimento não simultâneos, e aparelho
CN306115046S (zh) 背包(英伦风潮)
CN306126536S (zh) 包装盒(生物可降解环保型-全豆营养馒头)
CN306125731S (zh) 移门缓冲器(6018)
CN306103747S (zh) 礼品包装盒(2)
CN306122115S (zh) 手机收纳袋
CN306116461S (zh) 带外壳的果岭叉
CN306149277S (zh) 探测连接器
CN306056875S (zh) 置物架
CN306056171S (zh) 缝线休闲鞋(1)
CN306025006S (zh) 包装盒
CN306057707S (zh) 手柄(蟹形)
CN306104222S (zh) 电动车充电站控制器
CN306117512S (zh) 吊坠(四叶草之梦)
CN306126589S (zh) 包装袋(精良大米)
CN305901147S (zh) 护理床床头
CN305930900S (zh) 吸毛梳
CN305925668S (zh) 妆台(1961)
CN305925214S (zh) 床(01)
CN305925971S (zh) 餐盒内托
CN306125076S (zh) 拖把桶
CN305914308S (zh) 淋浴本体(b)
CN305919367S (zh) 防爆温度控制器
CN305912320S (zh) 充电插头

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220630